What We Look For

We often work with companies developing platform technologies that, though not currently working on CF, have novel technologies or assets that may be applicable to specific CF treatment challenges. The Foundation brings experience, expertise, and gold standard tools to empirically test most development candidates in relevant preclinical models.  

Genetic Medicines and Other Transformative Therapies 

• Approaches to restore, correct, or replace CFTR protein, CFTR RNA, or CFTR DNA carrying pathogenic mutations
• Viral and non-viral delivery approaches to target the correct cells for delivery of nucleic acids and proteins to organs affected by CF, including but not limited to the lung

Infectious Disease

• Treatments for pulmonary infections that affect people with CF
• Diagnostics for rapid and reliable detection of pathogenic pulmonary infections that affect people with CF

Manifestations

• Treatments to address other manifestations of CF including but not limited to pancreatic insufficiency and mucociliary clearance

Our Investment Approach

• Industry-standard due diligence processes on all prospective investments (e.g., scientific, operational, business, legal, financial)
• Agnostic of stage of development
• Flexible investment vehicles, with a preference for equity instruments

Contact Us

Is your company working on a technology or program that may align with our investment strategy? Contact us through the form below. We look forward to hearing from you.

Investment Inquires